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Background: Several rescue therapies have been used in patients with lamivudine (LAM)-resistant chronic hepatitis
B (CHB); however, the economic outcome of these therapies is unclear. The object of the current analysis was to
evaluate the lifetime cost-effectiveness of rescue therapies among patients with LAM-resistant CHB.
Methods: A Markov model was developed to simulate the clinical course of patients with LAM-resistant CHB. From
the perspective of Chinese health care, a lifetime cost-utility analysis was performedfor 4 rescue strategies: adefovir
(ADV), entecavir (ETV) or tenofovir (TDF) monotherapy and combination therapy using LAM and ADV. A
hypothetical cohort of 45-year-old patients with genotypic or clinical LAM-resistant CHB entered the model, and
the beginning health state was LAM-resistant CHB without other complications. The transition probabilities, efficacy
and resistance data for each rescue therapy as well as the costs and utility data were estimated from the literature.
The discount rate (3%) utilized for costs and benefits. Sensitivity analyses were used to explore the impact of
uncertainty on the results.
Results: In LAM-resistant HBeAg-positive and HBeAg-negative CHB cohorts, TDF monotherapy and combination
therapy were on the efficiency frontier for both positive and negative populations. Compared with no treatment,
the use of combination therapy cost an additional $6,531.7 to gain 1 additional quality-adjusted life year (QALY) for
HBeAg-positive patients and $4,571.7 to gain 1 additional QALY for HBeAg-negative patients. TDF monotherapy for
HBeAg-positive patients, shows greater increase in QALYs but higher incremental cost-effectiveness ratio (ICER) in
comparison with combination therapy. In probabilistic sensitivity analyses, combination therapy was the preferred
option for health care systems with limited health resources, such as Chinese health care system.
Conclusion: In Chinese patients with LAM-resistant CHB, combination therapy is a more cost-effective option than
the competing rescue therapies.
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The hepatitis B virus (HBV) infects about 350 to 400
million people worldwide (approximately 5% of the
world’s population), including approximately 112 million
Chinese people [1]. Chronic hepatitis B (CHB) infection
has high morbidity and mortality because the ongoing
viral replication increases the risk of cirrhosis and hepa-
tocellular carcinoma [2]. Consequently, the suppression* Correspondence: chenghuafeng@126.com
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reproduction in any medium, provided the orof HBV viral replication is one of the primary goals of
antiviral therapy [3].
Several oral nucleoside antiviral agents, such as lami-
vudine (LAM), adefovir (ADV), telbivudine (TBV), ente-
cavir (ETV) and tenofovir (TDF), have been approved
for the treatment of CHB. Because of their superior effi-
cacy and markedly low resistance, ETV and TDF have
been recommended as first-line options for treatment of
naïve CHB patients.[4] However, the high daily cost of
ETV and TDF limits their widespread use in areas with
limited health resources, such as in China [5]. LAM is
still accepted as the main antiviral agent in these areas,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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established safety and efficacy profile [6]. However, long-
term use of LAM is associated with a high rate of resist-
ance (up to 70% by the end of 5 years) due to mutation
at the YMDD motif [7]. Resistance to LAM could lead
to a virological breakthrough and is associated with
worse clinical outcomes [8]. Therefore, rescue strategies
for dealing with LAM resistance are becoming an im-
portant issue in areas where LAM is widely used. The
addition of ADV (a synthetic adenine nucleotide analog)
or ADV monotherapy has demonstrated efficacy against
LAM-resistant HBV in clinical trials and laboratory tests
[9-13]. Although ADV monotherapy has lower daily
costs than combination therapy, ADV monotherapy
increases the risk of ADV resistance in patients with
LAM-resistant CHB [14]. Because ETV and TDF have
relatively high potency and high genetic barriers to re-
sistance, switching to one of these two agents is an alter-
native [15-22]. However, because the rate of virological
breakthrough is approximately 40% in LAM-resistant
patients after 4 years of ETV therapy,[23] recent guide-
lines for managing CHB recommend that ETV be used
as a strategy for dealing with LAM resistance only when
the addition of ADV is not appropriate [3,24]. Although
these rescue strategies have been introduced into clinical
practice and have shown some health benefits for LAM-
resistant CHB patients, many problems remain. The cost
of these rescue strategies is a significant problem. To
our knowledge, there are no report comparing the cost-
effectiveness of different rescue strategies for patients
with LAM-resistant CHB.
The objective of the current study was to evaluate the
cost of 4 major rescue strategies for treating LAM-
resistant CHB: ADV monotherapy, combination therapy
using LAM and ADV, ETV 1mg monotherapy and TDF
monotherapy. To compare the 4 rescue strategies over a
lifetime, we developed a lifetime mathematical model for
LAM-resistant CHB that incorporates clinical and eco-
nomic data associated with CHB and its complications.
The results from our study could be helpful for physi-
cians and decision-makers.
Methods
Using decision analytic and Markov modeling techni-
ques, we constructed a mathematical model for HBeAg-
positive and HBeAg-negative LAM-resistant CHB. We
used this model to project the lifetime health and eco-
nomic outcomes associated with CHB and its complica-
tions from the perspective of Chinese health care. The
model was derived, in part, from our previous economic
model for naïve CHB [5]. Cost and health outcomes
were discounted at an annual rate of 3% [5]. The model
was implemented using R software (version 2.12.2; R De-
velopment Core Team, Vienna, Austria).Although multiple rescue strategies for LAM-resistant
CHB have been evaluated in clinical trials, the most
commonly recommended strategies are ADV mono-
therapy (10 mg/day), combination therapy using LAM
(100 mg/day) and ADV (10 mg/day), ETV monotherapy
(1 mg/day) and TDF monotherapy (300 mg/day) [6].
Therefore, these 4 rescue strategies were included to
compare their cost and effectiveness over time. After
patients develop LAM resistance, some will no longer
receive antiviral therapy because of the high daily cost of
the rescue agents. For this reason, we evaluated the out-
come of no treatment as a common comparator for
LAM-resistant CHB. Because the age of patients with
LAM-resistant CHB varies widely, we evaluated the out-
comes of patients with different ages at the onset of
LAM resistance. Serum HBV DNA level is an ideal sur-
rogate marker for antiviral therapies because of its inde-
pendent predictive ability for CHB disease progression
[25]. In this analysis, we use the serum HBV DNA level
as the main endpoint for the various rescue strategies
and for estimation of the risk of cirrhosis and hepatocel-
lular carcinoma.
Model overview
A Markov model consisting of 8 mutually exclusive
health states was developed to track the potential life-
time courses of CHB. These states characterize the dif-
ferent health conditions associated with CHB, as shown
schematically in Figure 1. A hypothetical cohort of 45-
year-old patients with genotypic or clinical LAM-
resistant CHB entered the model in the initial state, i.e.,
“lamivudine-resistant CHB.” Patients could move among
eight health states after one year, as indicated by arrows
in the Figure 1. According to the treatment response for
each rescue therapy, defined as HBV DNA<300-400 cop-
ies/ml by quantitative PCR, a patient could transition
from the initial state to either “virological response” or
“multi-resistant CHB.” Patients with a “virological re-
sponse” could also develop virological breakthrough due
to new antiviral resistance and transition to the multi-
resistant CHB health state. One important issue in the
course of CHB is the progression from CHB to cirrhosis
and hepatocellular carcinoma. The risk of disease pro-
gression is independently associated with the serum
HBV DNA level [25]. Patients in any of the three states
(“virological response,” “lamivudine-resistant CHB” and
“multi-resistant CHB”) could develop compensated cir-
rhosis and hepatocellular carcinoma. However, patients
in the virological response state would have a lower risk
of disease progression than patients in the other two
groups. Patients who develop compensated cirrhosis
would be at risk for decompensated cirrhosis and hepa-
tocellular carcinoma. Liver transplantation would be
















Figure 1 Markov diagram of the LAM-resistant CHB disease model. The ovals represent the eight mutually exclusive health states that the
patient with LAM-resistant CHB might experience over a lifetime. Patients begin in the “lamivudine-resistant CHB” state and might transit
between states or remain in their current health state during each 1-year cycle.
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ity of the progressed disease was also accounted for in
the model for estimation of the health outcomes. The
current analysis did not account for the natural mortality
for other causes. We extrapolated the lifetime outcomes
until all are dead or at the expected life-year (74 year of
age in China) [26].
Clinical data
The annual rates of progression were primarily derived
from the literature, as shown in Table 1. The REVEAL-
HBV study previously indicated that serum HBV DNA
levels are an independent marker for predicting theTable 1 Base-case annual probabilities associated with LAM-r
Initial state Entered state HBeAg (+
Estimate (%
Lamivudine-resistant CHB Compensated cirrhosis 2.7
Hepatocellular carcinoma 0.4
Virological response Compensated cirrhosis 0.5
Hepatocellular carcinoma 0.2
Multi-resistant CHB Compensated cirrhosis 2.7
Hepatocellular carcinoma 0.4
Compensated cirrhosis Decompensated cirrhosis 7.3
Hepatocellular carcinoma 3.4
Death 4.9
Decompensated cirrhosis Hepatocellular carcinoma 3.4
Liver transplantation 5
Death 14.4
Hepatocellular carcinoma Liver transplantation 5
Death 23.3
Liver transplantation Death 7
CHB, chronic hepatitis B.progression of CHB (cirrhosis and HCC). Therefore, we
assume that the progression depends on the serum HBV
DNA level, regardless of nucleoside resistance. Patients
with undetectable HBV DNA would be at the lowest risk
for developing compensated cirrhosis and HCC. The
proportions likely to receive liver transplantation for de-
compensated cirrhosis and HCC were derived from our
previously reported article [5].
Efficacy and resistance data (Table 2) for ADV mono-
therapy, combination therapy, ETV monotherapy and
TDF monotherapy were estimated from clinical trials. A
long-term clinical trial reported the four-year virological
response and resistance of ADV monotherapy foresistant CHB
) HBeAg (−) Source
) Range (%) Estimate (%) Range (%)
1.6-3.8 6.2 2.8-9.7 [27]
0.3-0.6 0.4 0.3-0.6 [27]
0.3-0.8 1.2 0.7-2 [25]
0.1-0.4 0.2 0.1-0.4 [25]
1.6-3.8 6.2 2.8-9.7 [27]
0.3-0.6 0.4 0.3-0.6 [27]
3.5-10 7.3 3.5-10 [28]
1-10 3.4 1-10 [28]
2-14 4.9 2-14 [28]
1-10 3.4 1-10 [28]
1-10 5 1-10 [5]
10-20 14.4 10-20 [5]
1-10 5 1-10 [5]
20-30 23.3 20-30 [5]
2-12 7 2-12 [5]
Table 2 Base-case cumulative virological response and HBV resistance probabilities for each rescue therapy









ADV monotherapy 1st year: 20.4 1st year: 1.6 1st year: 33.3 1st year: 0 [9]
2nd year: 33.2 2nd year: 20.7 2nd year: 44.0 2nd year: 16.9 [9]
3rd year: 38.8 3rd year: 39.5 3rd year: 47.5 3rd year: 31.4 [9]
4th year: 41.2 4th year: 51.6 4th year: 51.0 4th year: 42.4 [9]
ADV and LAM combination therapy 1st year: 47.0 1st year: 1.0 1st year: 60.0 1st year: 1.0 [29,30]
2nd year: 68.0 2nd year: 1.0 2nd year: 76.0 2nd year: 1.0 [29,30]
3rd year: 1.0 3rd year: 97.0 3rd year: 1.0 [29,30]
4th year: 8.0 4th year: 8.0 [29]
ETV monotherapy§ 1st year: 21.0 1st year: 1.0 1st year: 21.0 1st year: 1.0 [18,20,23]
2nd year: 39.5 2nd year: 10.9 2nd year: 39.5 2nd year: 10.9 [18,20,23]
3rd year: 25.2 3rd year: 25.2 [18,20,23]
4th year: 36.4 4th year: 36.4 [18,20,23]
TDF monotherapy§ 1st year: 45.8 1st year: 1.0 1st year: 45.8 1st year: 1.0 [22]
2nd year: 64.4 2nd year: 2.0 2nd year: 64.4 2nd year: 2.0 [22]
§No separate data for HBeAg(+) and HBeAg(−) cohorts were reported; we assumed that the response and resistant data were similar for both cohorts.
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sistance [9]. Cumulative virological responses at four
years were about 41.2% and 51.0% for the HBeAg(+) and
HBeAg(−) cohorts, and the cumulative resistance rates
were 51.6% and 42.4%, respectively. Data for combin-
ation therapy in patients with lamivudine-resistant
HBeAg(+) CHB and data on resistance were derived
from a clinical trial that included 132 lamivudine-
resistant CHB patients; the cumulative virological re-
sponse at two years was 68.0% [29]. For the HBeAg(−)
cohort, the cumulative virological response at three
years was 97.0% [30]. The cumulative resistance rate at
four years was 8%; we assumed that there was no differ-
ence in resistance for the two cohorts. For ETV and
TDF monotherapy, it was also assumed that the re-
sponse and resistance rates for both cohorts was similar
due to the absence of clinical data. The response rate for
ETV in lamivudine-refractory CHB was estimated from
a 96-week study [20]. The ETV resistance rate (21% at
first year and 39.5% at second year) for patients with
lamivudine resistance was estimated to be as high as
36.4%, based on a four-year assessment [23]. Because
few studies have reported the efficacy of TDF for
lamivudine-resistant CHB, we used data on TDF as a
rescue therapy for patients following the failure of both
lamivudine and adefovir. The cumulative virological
responses at one and two years was 45.8% and 64.4, re-
spectively [22]. The response to TDF was independent
of mutations conferring ADV resistance. Due to no evi-
dence of response and resistance data beyond the time-
frame of clinical trial, we assume that no health benefit
will be obtained from continuing the initial recuetherapies beyond the clinical observation time, and
patients who did not achieve a virological response
would be considered resistant to the initial recue therap-
ies and enter into the multi-resistant CHB state. We also
assume that the resistances beyond the observation
period were similar to those in the last year of the obser-
vation period. In our current analysis, we assumed the
resistance rate was identical with relapsed rate.
Cost and utility data
Direct health resource consumption was estimated from
the perspective of Chinese health care, including the cost
of medications, examinations, physician visits and la-
boratory tests (Table 3). Indirect costs such as lost prod-
uctivity were not included. The annual costs of the four
rescue therapies were calculated from the price of the
antiviral drugs obtained from the Shanghai Municipal
Bureau of Pricing. Several generic varieties of ADV are
available on the current Chinese market. Because the
median price of the generics was lower than Hepsera
(the brand name for ADV from GlaxoSmithKline), we
input the price of the generics into the model in the
base-case analysis. At present, TDF is still awaiting ap-
proval from the Chinese State Food and Drug Adminis-
tration, and no accurate price estimate is available. We
assumed that the cost of TDF (300 mg dosage) would be
similar to that of ETV ($6 per 500 mg dosage) in China
because, as first-line antiviral options for naïve CHB, the
costs of the two agents have been similar in other con-
texts [31,32]. Cost-related data for health states were
obtained from previous studies [5,33]. All costs were
converted to U.S. dollars (US $1 = CNY 6.5).
Table 3 Costs (2011 US$) and utilities input in the model
Parameter Base-case (range) Source/comment
Antiviral drug costs
Lamivudine (100 mg) 2.07(1.86-2.27) Local charge
Adefovir (10 mg) 2.31 (2.15-3.08) Local charge
Entecavir (1000 mg) 10.20 (8–10.2) Local charge









Multi-resistant CHB 138.7(104.62-209.23) Assumed similar to
lamivudine-resistant
CHB[5]
Virological response 138.7(104.62-209.23) [5]















Multi-resistant CHB 0.52(0.5-0.7) [34]
Virological response 0.71(0.65-0.8) [34]





Liver transplantation 0.7(0.54-0.76) [34]
CHB, chronic hepatitis B.
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published study using the standard gamble utility elicit-
ation technique (Table 3) [34]. The utilities for
lamivudine-resistant and multi-resistant CHB were
assumed to be equal to those for naïve CHB.
The annual discount rate for costs and utilities was
assigned as 3% in the current analysis [5].
Analysis
To evaluate the uncertainty of parameter values and the
robustness of the model, univariate sensitivity analyses
were performed for each parameter in the model over
the ranges shown in Tables 1, 2, 3. Ranges were sourced
from reported literatures, such as 95 CI %, or a range
±20% of the base case value when reported data were
not available. Two-way sensitivity analysis was used to
examine the uncertainty around the assumptionassociated with TDF, including the price and efficacy. To
estimate the simultaneous impact of parameter uncer-
tainty on the analysis, we also performed a probabilistic
sensitivity analysis (PSA), in which distributions were
assigned to the input parameters of the model (triangle
distributions for costs, beta distributions for probability
parameters and utilities). To identify the most cost-
effective therapy over the range of threshold values,
cost-effectiveness acceptability curves were plotted based
on the result of the PSA. We generated a cost-
effectiveness acceptability curve (CEAC) to identify the
strategy with the greatest probability of it being cost-
effective over a range of threshold values. CEAC could
demonstrate the level of uncertainty associated with an
option. The cost-effectiveness acceptability frontier
(CEAF) is, however, constructed from the CEAC of the
optimal option(s), and therefore only depicts uncertainty
through the probability of not selecting the most cost-
effective option [35]. Using scenario analyses, we evalu-
ated the impact of age at initial rescue therapy by setting
the age from 30 to 60 years.Results
The Markov model was used to estimate the clinical
benefits in quality adjusted lifeyears (QALY) and the
costs of the medication alternatives in the time horizon
period. The comparison among the treatment alterna-
tives was measured by the incremental cost-effectiveness
ratio (ICER). The cost-effectiveness threshold developed
is $11,034 (3× per capita GDP of China) and $38,376
(3× per capita GDP of Shanghai) for an additional qual-
ity-adjusted-life-year (QALY) gained according to WHO
recommendation [36,37]. This recommendation has
showed a potentiality of serving as a benchmark for
threshold in this Asian context [38]. A discount rate of
3% per year was adopted for the costs and results.Base-case analysis
In the LAM-resistant HBeAg-positive cohort, treatment
with TDF monotherapy resulted in 11.17 QALYs, and
the lifetime cumulative incidence of compensated cir-
rhosis, decompensated cirrhosis, HCC and death was
30.7%, 11.7%, 13.1% and 25.5%, respectively. The other
three competing rescue therapies yielded 9.25(ADV
monotherapy), 10.58(combination therapy) and 9.43
(ETV monotherapy) QALYs, respectively. In the LAM-
resistant HBeAg-negative cohort, treatment with com-
bination therapy achieved greater health benefits, which
resulted in 10.48 QALYs followed by10.48 (combination
therapy), 8.64 (ADV monotherapy)and8.51 (ETV mono-
therapy) QALYs, and a lifetime cumulative incidence of
compensated cirrhosis, decompensated cirrhosis, HCC
and death were 59.4%, 22.0%, 18.1% and 42.0%,
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presented in Table 4.
We evaluated the relative cost-effectiveness according
to the QALYs and costs associated with the various ther-
apies. The more expensive strategy was TDF in both
cohorts. In the HBeAg-positive cohort, ADV and ETV
monotherapy presented extended dominance and are
not as effective (lower QALYs) and efficient (higher
ICERs) than combination therapy. Combination therapy
was also acceptable and had the lowest ICER of any of
the rescue therapies. TDF monotherapy achieved
extended success, with more QALYs provided than com-
bination therapy but at a higher ICER. Among HBeAg-
negative patients, TDF and ETV monotherapy were
dominated; the combination therapy is more effective
than ADV and presents an ICER below the threshold of
China and Shanghai. The results are plotted in Figure 2.
Uncertainty and scenario analyses
One-way sensitivity analyses revealed that the model
was sensitive to some input parameters (Figure 3). In the
two cohorts, the most substantial impact factors include
the utilities of the CHB and virological response health
states, the probability of LAM-resistant and multi-
resistant CHB progression to compensated cirrhosis, and
the price of ADV per 10 mg. Other parameters, such as
cost of HCC and the probability of annual resistance to
combination therapy beyond the four years, are less
important.
In a scenario analysis in which we evaluated the eco-
nomic impact of age at the initiation of rescue therapy,
the ICER of the four rescue therapies compared with no
treatment increased with age (Figure 4A and B). For the
HBeAg-positive cohort, the ICER of the combinationTable 4 Modeled clinical outcomes of life-time in lamivudine
HBeAg status Positive
Treatment No ADV ADV and LAM ENT
Cumulative incidence of
compensated cirrhosis§
0.51 0.49 0.39 0.47
Cumulative incidence of
decompensated cirrhosis§
0.20 0.19 0.14 0.18
Cumulative incidence of HCC§ 0.19 0.18 0.15 0.18
Cumulative mortality§# 0.41 0.38 0.30 0.37
Expected life-years 24.00 24.48 25.61 24.64
QALYs 8.77 9.25 10.58 9.43
Total cost ($) 9478.0 13011.9 21284.9 25387
Incremental cost ($)& - 3533.8 11806.9 15908
Incremental QALYs& - 0.47 1.81 0.66
ICER† - 7468.0 6531.7 24268
§:Values are percentages, unless otherwise indicated.
#:Death is associated with hepatitis B.
&: “No treatment” was the baseline comparator.
†: ICER was calculated with the following equation: ICER=Incremental cost/Incrementherapy, which was dominant, fell below the threshold of
$11,034 (3× per capita GDP of China) and $38,376 (3×
per capita GDP of Shanghai), regardless of age. The TDF
monotherapy was lower than the threshold of $38,376
but would be higher than $11,034 if the patient’s age was
greater than 54. Among HBeAg negative, only TDF
exceeds the thresholds of $11,034 but it is lower than
the thresholds of $38,376.
Two-way sensitivity analysis for the variable TDF cost
against efficacy is shown in Figure 4C and D. Comparing
with “no treatment” for LAM-resistant HBeAg-positive
(C) and HBeAg-negative (D) CHB cohort, TDF strategy
must lower TDF price to $4.36 and $4.13 from an initial
cost of $6.0 to yield a lower than $6531.7 and$4571
ICER (where the initial efficacy equals the base-case
values), respectively. However, if the initial TDF price is
$6.0, ICER of TDF strategy was always higher than
$6531.7 and $4571 even when the efficacy was 1.5 times
of the base-case values, respectively.
A probabilistic sensitivity analysis of 1,000 simulations
revealed the probabilities of meeting the ICER thresh-
olds of $11,034 and $38,376 per additional QALY; the
results are shown in Figure 5. For the HBeAg-positive
cohort, the probabilities of cost-effectiveness being
achieved by combination therapy compared with no
treatment, ADV monotherapy, ETV monotherapy and
TDF monotherapy were 87.6%, 89.7%, 100.0% and
11.2%, respectively, under the $11,034 threshold. The
probabilities of cost-effectiveness under the $38,376
threshold were 99.7%, 99.5%, 100.0% and 89.5%, respect-
ively. Among HBeAg-negative patients, the probabilities
of cost-effectiveness being achieved with combination
therapy were all over 95% in comparison with all other
options except TDF monotherapy, regardless of whetherresistant CHB patient with rescue therapies
Negative
TNV No ADV ADV and LAM ENT TNV
0.31 0.80 0.76 0.59 0.76 0.53
0.12 0.33 0.30 0.22 0.31 0.21
0.13 0.25 0.23 0.18 0.23 0.17
0.25 0.64 0.58 0.42 0.59 0.41
25.88 20.62 21.83 24.14 21.65 23.69
11.17 7.76 8.64 10.48 8.51 10.36
.0 27556.3 13097.2 16229.5 25552.8 27556.3 32270.9
.9 22452.4 - 3132.3 12455.6 14459.2 19173.8
2.40 - 0.88 2.72 0.75 2.60
.9 9359.8 - 3552.6 4571.7 19157.1 7370.4
























































8.0 8.5 9.0 9.5 10.0
B.
Figure 2 Cost-effectiveness of rescue therapies for LAM-resistant HBeAg-positive (A) and HBeAg-negative (B) chronic hepatitis B.
The x-axis indicates the discounted lifetime quality-adjusted life-years (QALYs) for each therapy, and the y-axis indicates the total discounted
lifetime costs (US dollar). The oblique line connects “no treatment” and the most cost-effective therapies; therapies above the straight lines were
dominanated. Combination strategy uses LAM and ADV.
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showed that for the HBeAg-positive cohort the combin-
ation therapy and TDF monotherapy achieved the ma-
jority of probabilities of cost-effectiveness, and for the
HBeAg-negative cohort no treatment yielded the major-
ity of probabilities of cost-effectiveness when the WTP
thresholds are $11,034 and $38,376 (Figure 6).
Discussion
The high prevalence and morbidity of CHB pose heavy
social and financial burdens for China. Because of lim-
ited health resources, most naïve CHB patients can af-
ford only LAM as their first-line antiviral therapy; ETV
and TDF are too expensive. Consequently, about 70% of
patients will develop LAM resistance after 5 years. Selec-
tion of a cost-effective rescue therapy is an important
issue not only for patients but also for physicians and
decision-makers. The current economic analysis supplies
health and economic information on the four main res-
cue therapies for LAM-resistant CHB patients.
The current analysis suggests that the initiation of res-
cue therapies for LAM-resistant CHB with combination
therapy is likely to be more cost-effective than ADV,
ETV or TDF monotherapy. But for patients HBeAg
positive (Figure 5) the probabilistic sensitivity analysis
comparing combination therapy with TDF shows that
the probability to be costeffective is 11,2% for combin-
ation therapy compared to TDF under the $11,034threshold . ADV monotherapy was the least expensive of
the four rescue therapies, but its long-term health out-
comes were poorest. Although ADV monotherapy was
dominant, with the lowest ICER in HBeAg-negative
patients, we believe that combination therapy is the opti-
mal option. Results from PSA show it to be under the
ICER threshold of $11,034; it would be more cost-
effective compared to ADV monotherapy for about
96.1% of patients. In contrast, TDF monotherapy offered
the greatest health outcomes for HBeAg-positive
patients but was more resource-intensive than combin-
ation therapy (Table 4). In the HBeAg-positive CHB co-
hort, TDF monotherapy resulted in greater health
benefits but was more expensive than combination ther-
apy. Consequently, TDF monotherapy might be pre-
ferred in contexts with a high ICER or WTP threshold
(such as $38,376 per QALY). However, among HBeAg-
negative patients, TDF monotherapy did not show
extended dominance; rather, it may contribute to a lower
rate of virological response than combination therapy.
Because few studies on TDF as a rescue therapy for
HBeAg-negative CHB exist, the current estimation of
the virological response rate was derived from a study in
which only 33% of the patients had HBeAg-negative
CHB. We suggest that TDF monotherapy could offer
greater health benefits because the virological response
was greater in the HBeAg-negative CHB cohort than in
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Figure 3 Tornado diagram representing the net health benefit (QALYs, WTP=$11,034) determined by a one-way sensitivity analysis of
combination therapy (ADV+LMV) vs. no treatment for LAM-resistant HBeAg-positive (A) and HBeAg-negative (B) chronic hepatitis B.
The vertical line represents the base-case value for the net health benefit under WTP=$11,034.
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Figure 4 Scenario and two-way sensitivity analysis. The impact of age at initiation of LAM resistance on the incremental cost-effective ratio
(ICER) of rescue therapies in comparison with “no treatment” for LAM-resistant HBeAg-positive (A) and HBeAg-negative (B) chronic hepatitis B:
the x-axis indicates the age at initial rescue therapy, the y-axis indicates the ICER ($ per additional QALY), the bold horizontal two-dash and solid
lines represent the thresholds for China and Shanghai City, respectively. Varying the TDF cost and efficacy leads to different incremental cost-
effective ratio (ICER) of TDF monotherapy over “no treatment” for LAM-resistant HBeAg-positive (C) and HBeAg-negative (D) chronic hepatitis B:
the x-axis indicates the different cost of TDF, the y-axis indicates the different efficacy of TDF (the ratio relatively to the current using values in the
base-case analysis), the bold oblique lines represent that the ICERs for TDF strategy were equal to combination strategy, and grey and white areas
indicates the ICERs for TDF strategy were higher and lower than combination strategy, respectively. Combination strategy uses LAM and ADV.
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aging LAM-resistant CHB, which involve the addition of
ADV to LAM or TDF monotherapy [39-41].
Constrained economic conditions result in different
treatment options. Each province and city in China has
its own health care system, which determines medical
coverage based on local economic conditions [42,43].
Our analysis shows how health decision-makers couldselect affordable, cost-effective therapies. For example,
using 3× per capita GDP of Shanghai city as the WTP
threshold [44], TDF monotherapy might be recom-
mended for LAM-resistant HBeAg-positive CHB be-
cause this therapy achieves the greatest probability of
cost-effectiveness in comparison with no treatment and
other rescue therapies. However, from the perspective of
the rest of China, when the threshold decreases to
Combination therapy VS. No treatment
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Figure 5 Probabilistic results of the incremental cost-effectiveness differences between treatment with combination therapy (ADV
+LMV) and with (A) no treatment, (B) ADV monotherapy, (C) ETV monotherapy and (D) TDF monotherapy for a cohort of 1,000 LAM-
resistant HBeAg-positive and HBeAg-negative chronic hepatitis B patients. The y-axis represents the incremental costs. The x-axis represents
the incremental quality-adjusted life years (QALYs) gained. Dots that lie below the ICER threshold (the oblique lines) reflect simulations in which
the cost per additional QALY gained with combination therapy was below the ICER threshold.
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http://www.biomedcentral.com/1472-6963/12/385$11,034, combination therapy might be most affordable
and cost-effective.
Our analysis includes two other important findings.
First, based on recommendations by professional society
guidelines and expert opinion, surveillance for resistanceby monitoring of HBV DNA levels should be performed
for all patients receiving nucleoside analogs. Our sce-
nario analysis showed that an earlier age of rescue ther-
apy initiation is related to a lower ICER for all four
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Figure 6 Cost-effectiveness acceptability curve for rescue therapies for LAM-resistant HBeAg-positive (A) and HBeAg-negative (B)
chronic hepatitis B. The y-axis indicates the probability that a therapy is cost-effective across willingness to pay per QALY gained (x-axis). The
bold vertical two-dash and solid lines represent the thresholds for China and Shanghai City, respectively. Combination strategy uses LAM and
ADV.
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states have substantial impact on the results of the
model [5]. The current analysis finds a similar phe-
nomenon. To the best of our knowledge, the prejudice
and bias confronted by a person with CHB in China lead
to worse sociocultural conditions than are faced by
patients in western societies. CHB patients in China may
be discriminated against in employment, marriage and
education, as reflected in the lower utility values [45]. It
would be reasonable to expect that improvement of the
quality of life for patients with CHB would increase the
QALYs.
The analysis presented here has several limitations that
deserve consideration. First, most of the data for the
virological response and resistance were not estimated
from large-scale clinical trials. At present, ETV and TDF
are widely used for naïve CHB patients; in the future it
will be even more difficult to obtain large-scale data on
the management of LAM-resistant CHB. Second, no
clinical trial reporting virological response and resistance
data lasted longer than five years. We used assumed data
to calculate the lifetime outcomes. If long-term data be-
come available, the accuracy of the results could be
improved. Third, because no head-to-head trial has dir-
ectly compared the efficacy of the four rescue therapies,
our estimates were derived from various studies with
varying design, patient cohort, follow-up, and quality.
However, we examined the potential uncertainty of the
variables with a sensitivity analysis. The final result was
robust. Fourth, we did not evaluate potential treatmentafter a patient developed multiple resistance. In a con-
strained economic situation, such as China, many
patients cannot afford expensive rescue therapies and
would cease antiviral therapy after developing multiple
resistance. Fifth, the current analysis did not include
interferon-based strategies for dealing with LAM resist-
ance. Some studies have suggested that a significant pro-
portion of patients with LAM resistance who switched
to pegIFNa-2a from LAM had a similar response to
pegIFNa-2a as treatment-naïve patients [6]. Sixth, the
utility scores for patients with LAM-resistant and
multi-resistant CHB were assumed to be equal to those
for naïve CHB. However, these scores might be worse
in practice. One-way sensitivity analysis found that
lower utilities of LAM-resistant and multi-resistant
CHB would yield more health benefit. Finally, cumula-
tive virological response and HBV resistance probabil-
ities of ETV and TDF were assumed to be similar for
both cohorts. If new data is available, an update ana-
lysis is necessary. However, the clinical data call for
further study and a wider assessment. Nonetheless, be-
cause the current analysis reflects the current clinical
practice for dealing with LAM-resistant CHB, we be-
lieve that the results will be helpful for patients, physi-
cians and decision-makers.
Conclusions
In conclusion, our analysis reveals that the use of com-
bination therapy as a longer-term rescue therapy for
LAM-resistant CHB is more cost-effective than ADV,
Wu et al. BMC Health Services Research 2012, 12:385 Page 12 of 13
http://www.biomedcentral.com/1472-6963/12/385ETV and TDF monotherapy in China. TDF monother-
apy is a potential therapy under generous economic con-
ditions. After development of LAM resistance, rescue
therapy should be initiated as early as possible. Future
research is needed to evaluate rescue therapies further,
and economic analyses should be updated accordingly.
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